News

Center for Biosimilars1d
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, ...
Center for Biosimilars1d
Paving the Way for Equitable Biosimilar Access in Australian Dermatology Clinics
Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its ...
centerforbiosimilars2d
Joseph P. Fuhr, PhD
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars2d
Gary Fanjiang, MD, MBA, MS
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
Center for Biosimilars3d
Yesintek Biosimilar Shows Comparable Efficacy, Lower Immunogenicity Than Stelara, Says Elena Wolff-Holz, MD
Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to ...
centerforbiosimilars3d
Camlyn Masuda, PharmD, BCACP, CDCES
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars4d
Soni Gupta, MEc
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars4d
Juliana M. Reed
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars4d
Christopher M. Bruno, JD
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars4d
Hillel P. Cohen, PhD
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...
centerforbiosimilars4d
Anna Chen, PharmD, MS
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...